GT: Glanzmann thrombasthenia (hereditary deficiency of the platelet glycoprotein alphaIIbbeta3 integrin, previously called the glycoprotein [GP]IIb/IIIa receptor); HLA: human leukocyte antigen; RBCs: red blood cells; rFVIIa: recombinant activated factor VII; VTE: venous thromboembolism.
* Platelet transfusion and rFVIIa are often given together despite lack of high quality evidence that the combination is more effective than either given alone. Some individuals may use rFVIIa to avoid platelet transfusions, which carry a risk of developing antibodies to platelet GPIIb/IIIa and/or HLA or to treat bleeding if these antibodies have already developed. NovoSeven is approved for patients with GT at a dose of 90 mcg/kg. The dose is repeated approximately every 90 to 120 minutes until bleeding has stopped. Following surgery, dosing every 2 to 6 hours is reasonable until the concerns about hemostasis have resolved. Refer to product information for additional details.